[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Espinosa E, Morales S, Borrega P, Casas A, Madroñal C, Machengs I, Illarramendi JA, Lizón J, Moreno JA, Belón J, Janáriz J, de la Puente M, Checa T, Mel JR, González Barón M: Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemother Pharmacol; 2004 Dec;54(6):546-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
  • PURPOSE: Epirubicin and docetaxel are two of the most active drugs against breast carcinoma.
  • As the achievement of a pathological complete response (pCR) is important for survival of patients with locally advanced disease, we used both drugs as neoadjuvant chemotherapy.
  • PATIENTS AND METHODS: Women with locally advanced or inflammatory breast cancer received epirubicin 120 mg/m2 followed by docetaxel 75 mg/m2, both on day 1, every 21 days for four cycles.
  • The median age was 47 years, tumour stage was IIIA in 14 patients and IIIB in 36.
  • CONCLUSIONS: Docetaxel plus high-dose epirubicin showed promising activity in patients with locally advanced and inflammatory breast cancer, at the cost of moderate toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Epirubicin / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Middle Aged. Neoadjuvant Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316749.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


2. Stemmer SM, Rizel S, Hardan I, Adamo A, Neumann A, Goffman J, Brenner HJ, Pfeffer MR: The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study. J Clin Oncol; 2003 Jul 15;21(14):2713-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study.
  • PURPOSE: This phase II single-institution prospective, nonrandomized trial investigates high-dose adjuvant chemotherapy and locoregional radiotherapy in patients with breast cancer.
  • PATIENTS AND METHODS: 100 patients with high-risk stage II-III breast cancer received doxorubicin-based adjuvant chemotherapy followed by high-dose chemotherapy, stem-cell support, and locoregional radiotherapy.
  • CONCLUSION: In patients with high-risk stage II to III breast cancer, the inclusion of the IMN in the radiotherapy field was associated with a statistically significant increase in DFS and a borderline increase in OS.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Carcinoma / pathology. Carcinoma / radiotherapy. Lymphatic Irradiation
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Mastectomy / methods. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Prospective Studies. Risk Assessment. Single-Blind Method. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2004 Jun 1;22(11):2257-8; author reply 2258 [15169822.001]
  • [CommentIn] J Clin Oncol. 2004 Jun 1;22(11):2258-9; author reply 2259-60 [15169824.001]
  • (PMID = 12860949.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Favret AM, Carlson RW, Goffinet DR, Jeffrey SS, Dirbas FM, Stockdale FE: Locally advanced breast cancer: is surgery necessary? Breast J; 2001 Mar-Apr;7(2):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced breast cancer: is surgery necessary?
  • A retrospective analysis of the treatment of locally advanced breast cancer (LABC) was undertaken at Stanford Medical Center to assess the outcome of patients who did not undergo surgical removal of their tumors.
  • Between 1981 and 1998, 64 patients with locally advanced breast cancer were treated with induction chemotherapy, radiation with or without breast surgery, and additional chemotherapy.
  • Based on the clinical response to chemotherapy and patient preference, 44 (69%) patients received no local breast surgery.
  • Of the 65 locally advanced breast cancers in 64 patients, 26 (41%) were stage IIIA, 35 (55%) were stage IIIB, and 4 (6%) were stage IV (supraclavicular lymph nodes only).
  • These data indicate that the routine inclusion of breast surgery in a combined modality treatment program for LABC does not appear necessary for the majority of patients who experience a response to induction chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Mastectomy / utilization. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome. Unnecessary Procedures

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11328324.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; CAF protocol
  •  go-up   go-down


Advertisement
4. Yoshizawa H, Tanaka J, Kagamu H, Maruyama Y, Miyao H, Ito K, Sato T, Iwashima A, Suzuki E, Gejyo F: Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer; 2003 Sep 1;89(5):803-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
  • A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities and the response rate of carboplatin and 5-fluorouracil administered daily with concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer.
  • In a phase I/II clinical trial, patients with histologically documented, unresectable stage IIIA or IIIB non-small-cell lung cancer (NSCLC) were enrolled.
  • This combined therapy for locally advanced non-small-cell lung cancer is promising and shows acceptable toxicity.
  • [MeSH-major] Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / therapy. Fluorouracil / administration & dosage. Lung Neoplasms / therapy. Radiation-Sensitizing Agents / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1999 Aug;52(2):137-48 [10577699.001]
  • [Cites] Lung Cancer. 1994 Mar;10 Suppl 1:S239-44 [8087515.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1281-9 [11728688.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):134-9 [12007951.001]
  • [Cites] AJR Am J Roentgenol. 1976 Feb;126(2):229-35 [175693.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):1923-33 [6818194.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):539-47 [3009368.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Radiother Oncol. 1987 Jun;9(2):157-65 [3303163.001]
  • [Cites] Breast Cancer Res Treat. 1987 Nov;10(2):145-9 [3427223.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Feb;25(2):173-6 [2649374.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1543-55 [2167952.001]
  • [Cites] N Engl J Med. 1990 Oct 4;323(14):940-5 [2169587.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1183-90 [1646194.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):524-30 [1310160.001]
  • [Cites] J Natl Cancer Inst. 1992 Jan 1;84(1):58 [1310747.001]
  • [Cites] Oncology. 1992;49 Suppl 1:71-6; discussion 77 [1323815.001]
  • [Cites] Semin Oncol. 1992 Aug;19(4 Suppl 11):2-7 [1509277.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):452-8 [7844608.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):819-25 [7860394.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 1;87(3):198-205 [7707407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1065-70 [8648358.001]
  • [Cites] J Natl Cancer Inst. 1996 Sep 4;88(17):1210-5 [8780630.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):113-6 [9007136.001]
  • [Cites] Br J Cancer. 1998 Jul;78(2):257-62 [9683303.001]
  • [Cites] Ann Oncol. 1992 Aug;3 Suppl 3:33-7 [1327081.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6501-6 [1423296.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2A):461-4 [8017848.001]
  • [Cites] Semin Oncol. 1994 Jun;21(3 Suppl 6):79-90 [8052878.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):883-7 [11429215.001]
  • (PMID = 12942108.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2394482
  •  go-up   go-down


5. Fujitomi Y, Fujiyoshi K, Yasue K: [Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis]. Gan To Kagaku Ryoho; 2000 Feb;27(2):303-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improved QOL with cancer chemotherapy in two patients with breast cancer suffering form carcinomatous pleurisy and carcinomatous peritonitis].
  • One of the breast cancer patients introduced here suffered from recurrent carcinomatous pleurisy and the other from recurrent carcinomatous peritonitis.
  • The patient with recurrent carcinomatous pleurisy was a 47-year-old female with stage IIIa breast cancer.
  • The breast cancer was detected in a diagnosis of metastasis to the axillary lymph nodes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Peritonitis / drug therapy. Pleurisy / drug therapy. Quality of Life
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Medroxyprogesterone Acetate / administration & dosage. Middle Aged. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700906.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; C2QI4IOI2G / Medroxyprogesterone Acetate; U3P01618RT / Fluorouracil; 1-UFT protocol; CAF protocol
  •  go-up   go-down


6. Conti F, Carpano S, Sergi D, Di Lauro L, Amodio A, Vici P, Abbate MI, Ferranti FR, Viola G, Botti C, Foggi P, Sperduti I, Lopez M: [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results]. Clin Ter; 2007 Jul-Aug;158(4):331-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
  • [Transliterated title] CEF (ciclofosfamide, epirubicina, fluorouracile) ad alte dosi come chemioterapia primaria nel trattamento del carcinoma mammario localmente avanzato: risultati a lungo termine.
  • PURPOSE: To determine wether primary CEF is effective in locally advanced breast cancer, as measured by response, local recurrences, disease free survival (DFS) and overall survival (OS).
  • MATERIAL AND METHODS: From 1990 to 1998, 62 patients with stage III disease were enrolled into a prospective study at Regina Elena Institute for Cancer Research, Rome.
  • Inflammatory breast cancer (IBC) was included.
  • RESULTS: Seven IIIA patients had a median OS of 43 months (C.I.
  • Forty IIIB non inflammatory breast cancer patients had a median DFS of 87 months (C.I.
  • Ten-year OS was 28.6% for stage IIIA, 50.6% for stage IIIB and 36% for IBC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Agents, Hormonal / administration & dosage. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17953285.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Somlo G, Doroshow JH, Synold T, Longmate J, Reardon D, Chow W, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Shibata SI, Tetef ML, Yen Y, Kogut N, Schriber J, Alvarnas J: High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer; 2001 Jun 15;84(12):1591-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.
  • Between October 1995 and June 1998, 63 patients with high-risk primary [stage II with >or= 10 axillary nodes involved, stage IIIA or stage IIIB inflammatory carcinoma (n = 53)] or with stage IV responsive breast cancer (n = 10) received paclitaxel 150-775 mg/m(2)infused over 24 hours, doxorubicin 165 mg/m(2)as a continuous infusion over 96 hours, and cyclophosphamide 100 mg kg(-1).
  • Kaplan-Meier estimates of 30-month event-free and overall survival for patients with primary breast carcinoma are 65% (95% CI; 51-83%) and 77% (95% CI; 64-93%).

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Cancer Research Campaign.
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):225-33 [10655439.001]
  • [Cites] Hematol Cell Ther. 1999 Apr;41(2):71-4 [10344555.001]
  • [Cites] Acta Oncol. 2000;39(1):47-52 [10752653.001]
  • [Cites] Ther Drug Monit. 1985;7(4):455-60 [4082243.001]
  • [Cites] Br J Cancer. 1989 Jul;60(1):121-5 [2478178.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1824-30 [2511276.001]
  • [Cites] J Pharm Biomed Anal. 1990;8(2):159-64 [1982732.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1261-7 [1675263.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805 [1683908.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1132-43 [8501500.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1943-51 [7691998.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):532-8 [7907130.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1253-9 [8080512.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1678-85 [7512436.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1621-9 [7913721.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 8):19-23 [7939757.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):180-90 [7799018.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1463-72 [8622060.001]
  • [Cites] J Infus Chemother. 1996 Spring;6(2):69-73 [8809652.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1521-8 [9057632.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1870-9 [9164197.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1906-15 [9164201.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2882-93 [9256132.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1689-95 [9676843.001]
  • [Cites] Lancet. 1998 Aug 15;352(9127):515-21 [9716055.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):847-54 [9816240.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1008-14 [9849448.001]
  • [Cites] N Engl J Med. 2000 Apr 13;342(15):1069-76 [10760307.001]
  • (PMID = 11401310.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33572; United States / NCI NIH HHS / CA / CA62505
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2363687
  •  go-up   go-down


8. Fujii Y, Nakazawa K, Yoneto T, Shuzui Y: [A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pericardial tamponade caused by recurrent breast cancer treated with intrapericardial and intrapleural infusion of cisplatin (CDDP)].
  • Breast cancer rarely metastasizes to the pericardial cavity to cause cardiac tamponade.
  • We have recently experienced a case of pericardial tamponade due to recurrent breast cancer.
  • A 41-year-old woman who underwent modified radical mastectomy for a right breast cancer (T(1)N(3)M(0), Stage IIIA) 8 years and 8 months ago, was admitted for dyspnea and cough.
  • Based on cytodiagnosis of pericardial and pleural effusion, the diagnosis was pericardial and intrapleural metastases of the breast cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Cardiac Tamponade / drug therapy. Cisplatin / administration & dosage. Pleural Effusion, Malignant / drug therapy
  • [MeSH-minor] Adult. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Infusions, Intralesional. Pericardial Effusion / etiology. Pericardiocentesis. Pleural Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912534.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


9. Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y, Adjuvant CEF Research Group for Breast Cancer: Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer; 2010 Jul;17(3):190-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
  • METHODS: A total of 294 patients with axillary node-positive primary breast cancer of STAGE I-IIIa were randomly assigned to either CEF [cyclophosphamide (CPA) 500 mg/m(2) i.v. days 1 and 8; epirubicin (EPI) 60 mg/m(2) i.v. day 1; and 5-fluorouracil (5-FU) 500 mg/m(2) i.v. days 1 and 8] or CMF [CPA 500 mg/m(2) i.v. days 1 and 8; methotrexate (MTX) 40 mg/m(2) i.v. days 1 and 8; and 5-FU 500 mg/m(2) i.v. days 1 and 8].
  • Adverse drug reactions (ADRs) occurred more frequently in CEF.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Papillary / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575284.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Peppercorn J, Herndon J 2nd, Kornblith AB, Peters W, Ahles T, Vredenburgh J, Schwartz G, Shpall E, Hurd DD, Holland J, Winer E: Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer; 2005 Oct 15;104(8):1580-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
  • BACKGROUND: The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes.
  • METHODS: Two hundred forty-six patients with AJCC Stage IIA, IIB, or IIIA breast carcinoma who had > or = 10 positive lymph nodes and who were participants in Cancer and Leukemia Group B (CALGB) 9082 were enrolled in this companion study, CALGB 9066.
  • QOL was assessed at baseline and at 3 months, 12 months, 24 months, and 36 months using the Functional Living Index-Cancer (FLIC), the Psychosocial Adjustment to Illness Scale (PAIS)-Self Report, and the McCorkle Symptom Distress Scale (SDS).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Breast Neoplasms / therapy. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Carmustine / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16118805.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA04457; United States / NCI NIH HHS / CA / CA07968; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA11789; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31809; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA37135; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA47545; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA60138; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


11. Shen ZZ, Liu GY, Su FX, He PQ, Yang MT, Shi JY, Sheng Y, Zou Q, Li YF: [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study]. Zhonghua Zhong Liu Za Zhi; 2005 Feb;27(2):126-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
  • OBJECTIVE: To investigate the clinical response, pathological complete response (pCR), tumor resection rate and safety of neoadjuvant chemotherapy with docetaxel and epirubicin (ET) for locally advanced breast cancer (LABC).
  • Twenty patients had clinical stage IIIa disease, 15 had stage IIIb disease and 5 stage IV patients who had ipsilateral sura-clavicular metastasis.
  • Incidence of III/IV Grade neutropenia was 8.4%/14.0% of cycles, and 3 patients suffered from neutropenia with fever.
  • CONCLUSION: Neo-adjuvant chemotherapy with a combination of docetaxel and epirubicin is effective and well tolerated by women with locally advanced breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Male. Middle Aged. Neutropenia / chemically induced. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Remission Induction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946557.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; P88XT4IS4D / Paclitaxel; ET protocol
  •  go-up   go-down


12. Le Chevalier T, Lynch T: Adjuvant treatment of lung cancer: current status and potential applications of new regimens. Lung Cancer; 2004 Dec;46 Suppl 2:S33-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment of lung cancer: current status and potential applications of new regimens.
  • Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers diagnosed worldwide.
  • Surgical resection offers the best chance for cure for those patients diagnosed with early-stage disease; however, the vast majority of patients will eventually relapse.
  • Although results from a large meta-analysis of data on adjuvant chemotherapy suggested an absolute benefit of 5% at 5 years from cisplatin-based chemotherapy, a rate similar to that seen in breast and colon cancers where adjuvant chemotherapy is a standard of care, the use of adjuvant therapy in NSCLC remained controversial.
  • In addition, results of the International Adjuvant Lung Cancer Trial (IALT), which compared adjuvant cisplatin-based chemotherapy to observation in patients with resected stage-I-IIIA NSCLC, suggested that adjuvant therapy had the potential to prevent a substantial number of deaths each year.
  • Two recently reported landmark studies have demonstrated the survival advantages of adjuvant therapy for patients with early-stage NSCLC.
  • Docetaxel, one of the most active agents for advanced NSCLC, is also regularly used for locally advanced disease as part of neoadjuvant or combined-modality regimens.
  • As recent findings have established the value of adjuvant chemotherapy for early-stage NSCLC, agents such as docetaxel warrant rigorous evaluation in this setting.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Clinical Trials as Topic. Humans. Neoplasm Staging. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698530.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 18
  •  go-up   go-down


13. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA: Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol; 2007 Jan;18(1):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
  • BACKGROUND: Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer.
  • METHODS: The British Columbia Breast Cancer Outcomes database was used to identify women aged 45 years or older at the time of diagnosis with early-stage (I-IIIA) breast cancer who received tamoxifen and were disease free 5 years after diagnosis.
  • Ten-year breast cancer event rates and mortality were calculated as well as annualized hazard rates of recurrence.
  • Annual breast cancer risk between years 6 and 10 was, respectively, 2.2%, 3.5% and 7.6% for N0, N1 and N2 disease and 2.6% and 4.5% for T1 and T2 breast cancer.
  • CONCLUSION: T and N stages predicted late relapse and death from breast cancer in a population-based cohort of postmenopausal women.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. LETROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030545.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole
  •  go-up   go-down


14. Al-Tweigeri TA, Ajarim DS, Alsayed AA, Rahal MM, Alshabanah MO, Tulbah AM, Al-Malik OA, Fatani DM, El-Husseiny GA, Elkum NB, Ezzat AA: Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer. Med Oncol; 2010 Sep;27(3):571-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.
  • The objective of this study is to evaluate the efficacy and safety profile of the doxorubicin followed by cisplatin/docetaxel as primary chemotherapy for patients with locally advanced breast cancer (LABC).
  • The primary end point was pathologic complete response (pCR) in breast and axilla.
  • Fifty-nine patients were evaluable for analysis: median age: 41 years, premenopausal: 68%, median tumor size: 6.0 cm (4-10), Stage IIB: 32% and IIIA/IIIB: 68%, both ER/PR positive: 53%, Her2/neu (3+) by IHC staining: 29%.
  • Breast conserving surgery was performed in 44%, and MRM in 56%.
  • pCR in the breast was 30.5%, in axilla was 37%, and pCR in both breast and axilla was 24%.
  • The DFS and OS of patients who achieved complete pathologic response in breast and axilla were 78 and 100%, respectively, while 14 patients relapsed of which 46% were Her2 positive.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Disease-Free Survival. Doxorubicin / administration & dosage. Estrogens. Female. Genes, erbB-2. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Mastectomy, Modified Radical. Mastectomy, Segmental. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / pathology. Progesterone. Prospective Studies. Radiotherapy, Adjuvant. Tamoxifen / administration & dosage. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 2):10-4 [11284619.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2676-85 [15837982.001]
  • [Cites] Ann Oncol. 1997 Jul;8(7):663-7 [9296219.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1189-200 [17701939.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(1):57-61 [16752226.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):56-63 [15598939.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1456-66 [11896092.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):237-44 [11072788.001]
  • [Cites] Br J Surg. 1999 May;86(5):665-8 [10361191.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1005-12 [17047649.001]
  • [Cites] Clin Breast Cancer. 2005 Jun;6(2):163-8 [16001995.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):118S-124S [11560986.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18 Suppl):106S-111S [11560984.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4224-37 [11709566.001]
  • [Cites] Oncology. 2007;72(1-2):17-26 [17998786.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):968-74 [14997191.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1172-6 [17434897.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 3):28-37 [11301372.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):814-9 [18258991.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):286-92 [9888470.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2600-8 [12829681.001]
  • [Cites] Breast Cancer Res Treat. 1995 Apr;34(1):63-9 [7749161.001]
  • [Cites] Ann Oncol. 2004 May;15(5):751-8 [15111342.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):843-50 [12610183.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):778-85 [18258986.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2988-95 [15860854.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4911-6 [17214361.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2012-8 [17513805.001]
  • [Cites] Clin Breast Cancer. 2004 Dec;5(5):371-6 [15585076.001]
  • (PMID = 19526202.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 4G7DS2Q64Y / Progesterone; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol; 2001 Dec;28(6):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.
  • Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful.
  • Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurring multifunctional antiangiogenic agent.
  • Oral administration of Neovastat in mice with subcutaneous grafted breast cancer (DA3) cells showed a significant reduction in tumor volume.
  • Neovastat also decreased the number of lung metastases in the Lewis lung carcinoma model.
  • In the oncology field, 482 patients have received Neovastat, of which 146 with solid tumors were exposed to the drug for more than 6 months.
  • A phase III double-blind placebo-controlled study is being conducted to evaluate the efficacy of Neovastat in addition to induction chemotherapy/radiotherapy combined modality treatment in patients with unresectable non-small cell lung cancer stage IIIA and IIIB.
  • A second phase III randomized, double-blind placebo-controlled study evaluates the efficacy of Neovastat as a monotherapy in metastatic renal cell carcinoma patients who have progressed following a first-line immunotherapy.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Bone Marrow / blood supply. Bone Marrow / drug effects. Multiple Myeloma / drug therapy. Tissue Extracts / therapeutic use
  • [MeSH-minor] Animals. Cartilage / chemistry. Clinical Trials as Topic. Drug Screening Assays, Antitumor. Humans. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy. Neovascularization, Pathologic. Sharks

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11740820.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Tissue Extracts; 0 / shark cartilage extract
  • [Number-of-references] 42
  •  go-up   go-down


16. Moyses B, Haegele P, Rodier JF, Lehmann S, Petit T, Velten M, Schraub S: Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer. Clin Breast Cancer; 2002 Jan;2(4):304-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
  • Breast helical computed tomography (CT) was evaluated for use in assessing response to neoadjuvant chemotherapy and residual tumor volume.
  • Forty-three patients with large, inflammatory breast cancers (stage IIA, 12; IIB, 13; IIIA, 9; IIIB, 9), all histologically confirmed by core biopsy, were evaluated prior to and following neoadjuvant chemotherapy.
  • The breast helical CT procedure involved patients in the prone position using single acquisition during quiet respiration following intravenous injection of nonionic contrast material.
  • All tumors were clearly visible by breast helical CT, showing important tumor enhancement.
  • Breast helical CT can be very useful in the quantitative assessment of response to neoadjuvant chemotherapy and preoperative determination of residual tumor volume.
  • For this reason, it can be considered an alternative to breast magnetic resonance imaging because of its simplicity, rapidity, and accessibility.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Ductal, Breast / diagnostic imaging. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / diagnostic imaging. Carcinoma, Lobular / drug therapy. Drug Monitoring / methods. Neoadjuvant Therapy. Paclitaxel / analogs & derivatives. Taxoids. Tomography, X-Ray Computed / standards. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy, Needle. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Mammography / standards. Mastectomy. Middle Aged. Mitoxantrone / administration & dosage. Physical Examination / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11899363.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Fornasiero A, Ghiotto C, Daniele O, Favaretto AG, D'Amanzo P, Ziade A: Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma. Tumori; 2001 Jul-Aug;87(4):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant moderately high-dose chemotherapy with rh-G-CSF in locally advanced breast carcinoma.
  • The poor results of local treatment for locally advanced breast carcinoma (LABC) justify the use of chemotherapy as primary treatment.
  • Retrospective studies have shown a positive correlation between dose and response rate in advanced breast cancer.
  • METHODS: Inclusion criteria were the following: age <65 years, WHO performance status <2, histologically proven breast carcinoma, adequate hematologic, renal and hepatic function, stage IIIA or IIIB disease, and no metastatic disease.
  • Thirty-five patients had stage IIIA and 22 patients stage IIIB disease (7 with inflammatory disease).
  • To improve results the use of new drugs in controlled clinical trials seems warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Granulocyte Colony-Stimulating Factor / therapeutic use. Neutropenia / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Female. Filgrastim. Fluorouracil / administration & dosage. Fluorouracil / therapeutic use. Humans. Methotrexate / administration & dosage. Methotrexate / therapeutic use. Middle Aged. Recombinant Proteins

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11693799.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF regimen
  •  go-up   go-down






Advertisement